CareCost Syringes
1 × 300 mg
1 billing unit = 5 mg
300 mg dose → 60 billing units
J2357 · omalizumab
75, 150 and 300 mg single-use prefilled syringes · JZ on nearly every claim
Calculate this patient's units ↓300 mg subcutaneously every 4 weeks is a mid-table example · the dose and interval come off the label's IgE × weight table
This Xolair claim carries straight into Claim Check.
Claim Check builds the whole visit — J2357 units, the administration line, the modifiers and the Medicare allowed amount — and prices it against your payer's rate. The estimate turns the same visit into what the patient owes.
Free · No credit card · No sales call
Patient owes, 300 mg
Change the payer and the estimate re-prices against that payer's own published rate. The result is a good faith estimate for the patient.
37 payer price files · Commercial + Medicare · Copay and foundation status · Deductible, coinsurance and out-of-pocket math
Xolair J2357 is billed in units of 5 mg: ordered dose ÷ 5 mg = billing units. Unlike a flat-dose drug, the ordered dose itself is not fixed: chronic spontaneous urticaria is 150 or 300 mg, and asthma, nasal polyps and food allergy are read off the label's serum IgE × body-weight table, from 75 mg up to 600 mg. Whichever dose is ordered, the unit math is the same division by 5: a 300 mg dose is 300 ÷ 5 = 60 billing units.
Xolair ships as single-dose prefilled syringes in three sizes (75 mg, 150 mg and 300 mg), and every dose is built from whole syringes with the least waste, never a partial draw: 300 mg is one 300 mg syringe, 225 mg is a 150 mg plus a 75 mg syringe, and so on. Because nothing is drawn and left over, JZ (no drug discarded) is the modifier on virtually every Xolair claim, and there is no JW math to do.
The dose is set once. Serum total IgE and body weight, measured before the first injection, fix the dose and interval from the table for the whole course; the label does not call for re-dosing on an IgE level drawn during treatment. Chronic spontaneous urticaria is the exception: its 150 or 300 mg dose was never dependent on IgE or weight to begin with.
Medicare pays $9.1374 per mg (ASP+6%, $45.687 per 5 mg unit), effective for claims in Q4
2026, pricing the 60-unit, 300 mg dose above at $2,741.22.
| Dose | Syringes | Billing units |
|---|---|---|
| 75 mg | 1 × 75 mg | 15 |
| 150 mg | 1 × 150 mg | 30 |
| 225 mg | 150 mg + 75 mg | 45 |
| 300 mg | 1 × 300 mg | 60 |
| 375 mg | 300 mg + 75 mg | 75 |
| 600 mg | 2 × 300 mg | 120 |
Every dose in the label's IgE × weight table is built from whole 75, 150 and 300 mg syringes with the least waste; the engine never draws a partial syringe. Two-syringe doses (225, 375 and 600 mg) are two separate injections and two 96372 lines, the second reported with modifier 59 or XS on most payers' edits. The MUE for J2357 is 120 units per day, exactly the 600 mg ceiling in this table; 96372's own MUE is 4. Chronic spontaneous urticaria uses only the 150 mg and 300 mg rows; asthma, nasal polyps and food allergy can land on any row, depending on the patient's pre-treatment IgE and weight.
JZ on every Xolair claim: a dose is always whole syringes (75, 150 and 300 mg, alone or combined), so nothing is ever drawn and left over to discard, and JW does not apply.
96372 covers a therapeutic, prophylactic, or diagnostic injection given subcutaneously or intramuscularly. Xolair's subcutaneous injection is billed with 96372 alone; there is no infusion time to report, so the infusion-administration codes (96413 initial hour, 96415 each additional hour) used by IV biologics do not apply. Xolair is also not a chemotherapeutic agent, so the chemo-injection code 96401 does not apply either. A dose built from two syringes (225, 375 or 600 mg) is two separate injections and two 96372 lines, not one line at a higher unit count. The visit itself typically runs about 30 minutes, including an observation period after the injection.
Xolair ships as single-dose prefilled syringes or autoinjectors in three sizes (75 mg/0.5 mL, 150 mg/mL and 300 mg/2 mL), plus a 150 mg lyophilized single-dose vial that the label's dosing table is not built from. Lead NDC 50242-227-01, the 300 mg prefilled syringe (Genentech, labeler 50242). See the FDA Xolair label (BLA103976) for full dosing and administration instructions.
J2357 is Xolair's own code, and no omalizumab biosimilar carries a CMS payment rate in the pricing files this site reads, so none is listed here. The other IgE- and eosinophil-targeted respiratory biologics are separate molecules under their own HCPCS: Nucala (mepolizumab, J2182), Fasenra (benralizumab, J0517), Tezspire (tezepelumab-ekko, J2356) and Cinqair (reslizumab, J2786). Each bills its own code and its own per-mg unit conversion; none of them substitutes for J2357 on a claim. See the HCPCS hub for coding across the full family. The Medicare rate for every quarter is on the cost page →
60 billing units. Xolair J2357 bills 1 unit per 5 mg, so a 300 mg dose is 300 divided by 5, or 60 units.
J2357. No omalizumab biosimilar carries a CMS payment rate yet, so J2357 is the only code this site prices for Xolair; the other respiratory biologics payers step through first — Nucala, Fasenra, Tezspire and Cinqair — each bill their own J-code, not J2357.
JZ on every claim. A dose is always built from whole 75 mg, 150 mg and 300 mg syringes with the least waste, so nothing is ever drawn and discarded. JW does not apply.
No. Xolair is a subcutaneous injection billed with 96372, not an infusion
administration code — there is no infusion time, initial hour, or additional hour to report.
The IV infusion codes 96413 and 96415 do not apply at any dose, and neither
does the chemotherapy injection code 96401: omalizumab is not a chemotherapeutic agent.
Reporting a split dose (225, 375 or 600 mg, built from two syringes) as a single injection line instead of two separate 96372 lines, or dividing the ordered dose by 1 mg instead of the correct 5 mg unit.
Every 4 weeks for chronic spontaneous urticaria, the only fixed-dose indication (150 or 300 mg). Asthma, nasal polyps and food allergy are dosed every 2 or 4 weeks off the same IgE times weight table, so the interval varies by patient.
$9.1374 per mg (ASP+6%, $45.687 per 5 mg unit), effective for claims in Q4 2026 — $2,741.22 for the 60-unit, 300 mg dose.
Data current: pricing Q4 2026 · payer policies Aug 2026
Sources: CMS ASP pricing files (Q4 2026); Medicare physician fee schedule (96372, national non-facility); FDA-approved prescribing information (Xolair label, Genentech, BLA103976); CMS single-dose container JW/JZ policy (effective July 1, 2023); CPT codebook administration-code guidance; 28 commercial payer medical policies verified against the CareCost Clearance coverage corpus.
Reviewed September 20, 2026 by Erin Rose, CareCost Estimate founder. Methodology →